CCM
LENZ

CAAS Capital Management’s LENZ Therapeutics LENZ Stock Holding History

CAAS Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,714
Closed -$656K – 1078
2021
Q3 		$656K Hold
5,714
– – 0.01% 573
2021
Q2 		$1.23M Buy
+5,714
New +$995K 0.02% 503

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAAS Capital Management's LENZ Position: Q4 2021 in Review

CAAS Capital Management sold out of LENZ Therapeutics (LENZ) in Q4 2021, closing a stake of 5,714 shares — an estimated $656K sold.

CAAS Capital Management first reported a position in LENZ in Q2 2021 and held it in 2 quarters. The position peaked at $1.23M in Q2 2021. 58 funds tracked by Wall St. Rank hold LENZ as of Q4 2021.

  • CAAS Capital Management reported no remaining LENZ Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 5,714 LENZ Therapeutics shares in Q4 2021, an estimated $656K.
  • CAAS Capital Management first reported a position in LENZ Therapeutics in Q2 2021 and held it in 2 quarters.
  • CAAS Capital Management's LENZ Therapeutics position peaked at $1.23M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.